Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 189, Issue 1, Pages 128-132Publisher
WILEY
DOI: 10.1111/bjh.16296
Keywords
Hodgkin lymphoma; paediatric; neuropathy
Categories
Funding
- Cancer Research UK [C13431/A8315]
Ask authors/readers for more resources
This phase II trial was designed to determine the safety and efficacy of a modified paediatric risk-stratified protocol in young adults (18-30 years) with classical Hodgkin Lymphoma. The primary end-point was neurotoxicity rate. The incidence of grade 3 neurotoxicity was 11% (80% CI, 5-19%); a true rate of neuropathy of >15% cannot be excluded. Neuropathy and associated deterioration in quality of life was largely reversible. The overall response rate was 100% with 40% complete remission (CR) rate. Twelve months disease-free survival (DFS) was 91%. We demonstrate that a risk-stratified paediatric combined modality treatment approach can be delivered to young adults without significant irreversible neuropathy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available